Does Rallies show 13F holders for SUPN?

Yes. Rallies tracks hedge fund and 13F ownership data for SUPN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SUPN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SUPN. It does not provide personalized investment advice.

SUPN (Supernus Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded Healthcare sector company. As of May 21, 2026, SUPN trades at $48.47 with a market cap of $2.81B and a P/E ratio of -96.00. SUPN moved +2.27% today. Year to date, SUPN is -1.44%; over the trailing twelve months it is +46.66%. Its 52-week range spans $29.16 to $59.68. Analyst consensus is strong buy with an average price target of $63.17. Rallies surfaces SUPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SUPN stock?

Hedge funds tracked by Rallies that own SUPN include Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Supernus Pharmaceuticals, Inc..

SUPN Key Metrics

Key financial metrics for SUPN
Metric	Value
Price	$48.47
Market Cap	$2.81B
P/E Ratio	-96.00
EPS	$-0.51
Dividend Yield	0.00%
52-Week High	$59.68
52-Week Low	$29.16
Volume	0
Avg Volume	0
Revenue (TTM)	$776.83M
Net Income	$-29.02M
Gross Margin	89.42%

Top Hedge Funds Holding SUPN

Farallon Capital holds 4.00K shares of SUPN, changed +0.00% as of Mar 31, 2026.

Latest SUPN News

Supernus Pharmaceuticals Posts Record Q4 2025 Revenue Growth — Feb 25, 2026
Supernus Q4 Revenue Rises 21.5% to $211.6M; EPS of $0.92 Beats Estimates — Feb 25, 2026
Biogen Q4 Beat Sparks $66M Zurzuvae Sales, Boosting Supernus Partnership — Feb 6, 2026

Recent SUPN Insider Trades

Bhatt Padmanabh P. sold 6.84K (~$338.82K) on Mar 18, 2026.
Bhatt Padmanabh P. sold 412 (~$20.80K) on Mar 18, 2026.
Bhatt Padmanabh P. sold 27.71K (~$1.38M) on Mar 17, 2026.

SUPN Analyst Consensus

6 analysts cover SUPN: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.17.

Common questions about SUPN

Who owns SUPN stock?: Hedge funds tracked by Rallies that own SUPN include Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Supernus Pharmaceuticals, Inc..
Does Rallies show 13F holders for SUPN?: Yes. Rallies tracks hedge fund and 13F ownership data for SUPN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SUPN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SUPN. It does not provide personalized investment advice.